Core Insights - Profusa, Inc. has successfully reduced its net debt from $34 million to $14 million as of October 31, 2025, following a merger with NorthView Acquisition Corporation [2][9] - The company aims to achieve potential revenues of $200 to $250 million by 2030, with near-term revenue targets of $0.5 to $2 million for 2026 and $9 to $13 million for 2027 [4] Business Highlights - The merger with NorthView Acquisition Corporation was completed, resulting in a company equity value of $155 million [8] - Manufacturing capabilities have been built out, with plans to begin product shipments and generate revenue in early 2026 [8] - Profusa has expanded its sales footprint in Europe, currently covering approximately 35% of the European population for its Lumee™ Oxygen tissue monitoring platform [8] - The company has entered into several clinical and commercial collaborations with prominent vascular surgeons [8] Financial Highlights - Profusa raised $12 million in gross proceeds from a convertible PIPE note, with $10 million remaining available [9] - An additional $7 million was raised through an Equity Line of Credit (ELOC) as of October 31, 2025, with $93 million still available [9] - Cash and cash equivalents increased to $4 million, and net debt was reduced to $14 million as of October 31, 2025, down from $48 million last quarter [9]